[HTML][HTML] The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - Blood, 2012 - Elsevier
Abstract Abstract 1678 Background. Imatinib mesylate (IM) is the therapeutic standard for
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
[引用][C] The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - BLOOD, 2012 - iris.unito.it
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A …
F Castagnetti, G Gugliotta, M Breccia, G Specchia… - 2012 - ashpublications.org
Abstract Abstract 1678 Background. Imatinib mesylate (IM) is the therapeutic standard for
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …
chronic myeloid leukemia (CML), but nilotinib and dasatinib, at least in selected patients …